Evidence map›Paper›PMID 41572435›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Islet Amyloid Polypeptide Modelled to Simulate Diabetes Co-Oligomerized with β-Amyloid 1-42 Reproducing the Pathological Cascade of Alzheimer's Disease in Human Cerebral Organoids.

Jin Yan, Zhimeng Tang, Yanyu Luo, Bin Liu, Xinxin Huang, Jun Wei, Feng Yue

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jin YanState Key Laboratory of Digital Medical Engineering, School of Biomedical Engineering, Hainan University, Sanya, China.
Zhimeng TangState Key Laboratory of Digital Medical Engineering, School of Biomedical Engineering, Hainan University, Sanya, China.
Yanyu LuoState Key Laboratory of Digital Medical Engineering, School of Biomedical Engineering, Hainan University, Sanya, China.
Bin LiuState Key Laboratory of Digital Medical Engineering, School of Biomedical Engineering, Hainan University, Sanya, China.
Xinxin HuangState Key Laboratory of Digital Medical Engineering, School of Biomedical Engineering, Hainan University, Sanya, China.
Jun WeiiRegene Therapeutics Co. Ltd., Chengdu, China.
Feng YueState Key Laboratory of Digital Medical Engineering, School of Biomedical Engineering, Hainan University, Sanya, China.

Funding

Project of Collaborative Innovation Center of One Health XTCX2022JKC05STI2030-Major Projects 2021ZD0200900
6 · The paper itself

Abstract

Previous animal models of sporadic Alzheimer's disease (sAD), based on the β-amyloid (Aβ) cascade hypothesis and induced by Aβ1-42 oligomers (AβO), only recapitulated early AD pathological features. sAD cerebral organoids (COs) model employed Aβ coculture approach and found no typical features of AD pathology. Type 2 diabetes (T2DM) is one of the most important modifiable AD risk factors, so we hypothesize that T2DM could substantially exacerbate Aβ neurotoxicity and reproduce typical AD pathology. Human islet amyloid polypeptide (hIAPP) was used to mimic T2DM and was co-oligomerized with Aβ1-42 peptide, and delivered to the central of human iPSC-derived mature COs through intermittently repeated microinjections, so as to simulate the chronic exposure to Aβ within the brain. The Aβ42-hIAPP co-oligomers induced a pathological phenotype more closely resembling the pathological features of advanced AD, notably, neuronal density showed significant reduction, with 3.2 times more neuronal death. Dynamic metabolomic analysis revealed the metabolic pathways and differential metabolites that may be correlated to the primary mechanism underlying the enhanced neurotoxic effects and accelerated AD pathology. Furthermore, this study developed a sAD CO model more resembling the pathological features of advanced AD, which potentially provides a valuable platform for AD pathogenesis research and novel drug screening.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBrainDiabetes Mellitus, Type 2Islet Amyloid PolypeptideOrganoidsPeptide FragmentsHumansAmyloid beta-Peptidesamyloid beta-protein (1-42)Islet Amyloid PolypeptidePeptide FragmentsAlzheimer's disease, human cerebral organoids, β‐amyloid oligomers, neuronal deathType 2 diabetes mellitus, islet amyloid polypeptide

Identifiers

PMID41572435
PMCPMC13042975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.